Infectious Disease Flashcards
IE: Factors associated with increased risk of embolization
S. aureus IE, mobile vegetations >10 mm in diameter, and infection involving the mitral valve anterior leaflet
Definite IE requires:
2 major criteria or
1 major 3 minor or
5 minor
Possible IE definition:
1 major + 1 minor or
3 minor
Definition of “evidence of endocardial involvement” in Duke criteria
Positive echocardiogram:
- Oscillating intracardiac mass on valve or supporting structures or in the path of regurgitant jets or in implanted material, in the absence of an alternative anatomic explanation, or
- Abscess, or
- New partial dehiscence of prosthetic valve,
or
New valvular regurgitation (increase or change in preexisting murmur not sufficient)
Negative TEE but IE still likely, next dx step:
Repeat TEE in 7-10 daysC
Imaging comparable to TEE in detection of vegetations and possibly superior in defining paravalvulaar infection
Cardiac CT angiogram (CTA)
Drug of choice for streptococci endocarditis
Penicillin + Gentamicin regimen (duration depends on sensitivity)
Preferred duration of treatment for PVE
6 weeks
Used in streptococci IE for patients with immediate (urticarial) severe penicillin allergy
Vancomycin
Dose of gentamicin for Streptococcal IE
Gentamicin 3mg/kg daily IV or IM as a single dose or divided into equal doses
Duration:
2 weeks if penicillin susceptible and relatively penicillin-resistant
6 weeks if moderately penicillin-resistant strep
Preferred cell wall-active agent for use in combination with gentamicin for Enterococci IE
Ampicillin or penicillin
Regimen:
Penicillin G (4–5 mU IV q4h) plus gentamicin (1 mg/ kg IV q8h), both for 4–6 weeks
Ampicillin (2 g IV q4h) plus gentamicind (1 mg/kg IV q8h), both for 4–6 weeks
If penicillin allergic or isolates are resistant to penicillin/ampicillin: may use Vancomycin
Alternative regimen for E. faecalis (not E. faecium) if strains possess high level gentamicin resistance
Ampicillin-Ceftriaxone
Ampicillin (2 g IV q4h) plus ceftriaxone (2 g IV q12h), both for 6 weeks
Multidrug regimen for MRSA PVE
VAN + Genta (2 weeks only) + Rif
Vancomycin (15 mg/kg IV q12h for 6–8 weeks)
plus
Gentamicin (1 mg/kg IM or IV q8h for 2 weeks)
plus
Rifampin (300 mg PO q8h for 6–8 weeks)
Multidrug regimen for MSSA PVE
Naf/oxa/flucloxa + Genta 2 weeks only) + Rif
Nafcillin, oxacillin, or flucloxacillin (2 g IV q4h for 6–8 weeks)
plus
Gentamicin (1 mg/kg IM or IV q8h for 2 weeks)
plus
Rifampin (300 mg PO q8h for 6–8 weeks)
Regimen for MRSA NVE
Vancomycin (15 mg/kg IV q8–12h) or daptomycin (8–10 mg/kg daily) for 6 weeks
Drug of choice for febrile patients in whom prolonged neutropenia (>7 days) is anticipated
(1) ceftazidime or cefepime
(2) piperacillin/tazobactam
(3) imipenem/cilastatin or meropenem
When to initiate and stop G-CSF / GM-CSF
Start 24-72h after chemotherapy
Continue until ANC is 10,000 /uL
Do not use concurrently with chemo or radiation therapy
Fever of unknown origin work up (required)
TB: tuberculin skin test (TST) or interferon γ release assay (IGRA)
Inflammation: ESR, CRP, LDH, Ferritin
Hema: CBC: platelet count; leukocyte count and differential; hemoglobin, protein electrophoresis
Immunologic: antinuclear antibodies, and rheumatoid factor
GI: Alkaline phosphatase, ALT, AST
Renal: Electrolytes, creatinine, total protein, urinalysis, creatine kinase
Cultures: Blood cultures (n = 3)
Urine culture
Imaging: chest x-ray, Abdominal ultrasonography
Most common among the neoplasms that present with FUO
Malignant lymphoma
Next work up in FUO after obligatory investigations, manipulation with thermometer and drug fever excluded, and still with misleading or absent PDCs
Cryogobulin and fundoscopy
> FDG-PET/CT or gallium scan/labeled leukocyte scintigraphy
If normal, repeat history and PE and PDC driven invasive testing
If still no diagnosis, late state work up is chest CT and abdominal CT, temporal artery biopsy >55y
Tx if still with no dx for FUO after chest and abdominal CT and temporal artery biopsy
Stable: follow up and consider NSAID tx
Deterioration: further tests and consider therapeutic trial with Anakinra
Condition that may increase the risk of an adverse event or that may compromise the ability of the vaccine to evoke immunity
Precaution
Condition that increases the risk of a serious adverse reaction to vaccination
Contraindication
Permanent contraindications to vaccination
Severe allergic reaction to a vaccine component or following a prior dose
Encephalopathy not due to another identifiable cause occurring within 7 days of pertussis vaccination
Gold standard for a diagnosis of HIV infection
positive EIA with a positive HIV RNA assay